Nanoform says CESS manufacturing undercuts spray-dried ASD costs in industry analysis

• Nanoform published an industry analysis positioning its CESS technology as lower-cost than spray-dried amorphous solid dispersions.
• The analysis cites a scale-up factor above 1,000,000, with commercial output in kilograms per hour and multi-ton annual capacity.
• CESS is presented as reducing cost of goods via higher yields, lower capital needs, simplified downstream processing, and less excipient use.
• The report highlights higher drug loading versus ASDs, citing nanoenzalutamide at 40% versus 12% in a marketed ASD benchmark.
• CESS is positioned as more sustainable than spray drying by using recycled pharmaceutical-grade CO2 instead of organic solvents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanoform Finland plc published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.